A Study to Evaluate Safety, Tolerability, and PK of DA-7503 in Healthy Adult and Elderly Participants - Trial NCT06391827
Access comprehensive clinical trial information for NCT06391827 through Pure Global AI's free database. This Phase 1 trial is sponsored by Dong-A ST Co., Ltd. and is currently Not yet recruiting. The study focuses on Healthy. Target enrollment is 72 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Dong-A ST Co., Ltd.
Timeline & Enrollment
Phase 1
May 07, 2024
May 31, 2025
Primary Outcome
Pharmacokinetics of DA-7503 single dose oral administration,Pharmacokinetics of DA-7503 single dose oral administration,Pharmacokinetics of DA-7503 multiple dose oral administration,Pharmacokinetics of DA-7503 multiple dose oral administration,Pharmacokinetics of DA-7503 multiple dose oral administration,Pharmacokinetics of DA-7503 multiple dose oral administration
Summary
This is a double-blind, placebo-controlled, randomized, phase 1 study to evaluate safety,
 tolerability, and pharmacokinetics of orally administered DA-7503 after single and multiple
 ascending dose regimens in healthy adult and elderly participants
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06391827
Non-Device Trial